Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsIntegrated therapy for HIV and tuberculosisTuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected childrenGetting to 90-90-90 in paediatric HIV: What is needed?Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.AtriplaR/anti-TB combination in TB/HIV patients. Drug in focusInitial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.Initiating antiretrovirals during tuberculosis treatment: a drug safety review.Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.TB and HIV Therapeutics: Pharmacology Research Priorities.Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.Clinical pharmacology, efficacy and safety of atazanavir: a review.Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In VitroPharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe.Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects.Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa.
P2860
Q24631021-51EB8FF0-0CA9-47FF-A43B-55A21E360A2DQ26749428-00B132D9-A937-455F-8BC2-F7CA92C23D54Q26774267-A405FBE2-9A51-4BA2-B56B-30AD56EF68F5Q30385352-295C7EDD-D565-46F0-A801-D5DFFF1D33FFQ33712438-A872CA3E-CB2A-4ADB-B775-0695EAC41CB3Q33839294-EDE0B544-3680-4C8E-A1CC-9BBA2D921403Q34083071-102BE048-3A6E-45AE-A976-53FB1DF0587EQ34159649-BB657B9B-776E-42F3-8EA8-859304257079Q34427442-CCF13B59-B9BD-440B-9F03-F0998028BA80Q35043048-506235DD-7478-4DA4-A80D-50DD21BDEF4CQ35350315-6299BBCB-E073-420E-894B-1E6325A4ED9EQ35629777-96691278-89C6-4520-8C46-76C2C5165FB0Q36094771-E7482DBB-F417-47CE-863C-8A6048709606Q36099838-5DEB0572-46DE-4051-9482-71228A6CECA0Q37121902-F4397C9C-69E1-4C08-B386-A5CD0D8750CAQ37622972-47AA77D5-8587-4DA9-BF5B-7AB343A52286Q37846672-00D3C191-3740-40C1-A0D7-A1FCF46D8E3AQ38207924-79E2F468-7B1F-4966-97D6-135BD2B14405Q38963389-ADB54918-EF29-4B5B-BEED-FC5707C6E0AFQ42164262-403E9CE5-5EDA-441E-A2EE-57331668413DQ46558204-30D36E0F-1892-4A7A-974A-3C56A6B96C4DQ51694212-89B09724-8823-4B3A-8BA6-C39C851851F6Q53694036-097BB458-1063-4548-9477-7F378740A6B8
P2860
Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Effect of rifampin on steady-s ...... tonavir in healthy volunteers.
@ast
Effect of rifampin on steady-s ...... tonavir in healthy volunteers.
@en
type
label
Effect of rifampin on steady-s ...... tonavir in healthy volunteers.
@ast
Effect of rifampin on steady-s ...... tonavir in healthy volunteers.
@en
prefLabel
Effect of rifampin on steady-s ...... tonavir in healthy volunteers.
@ast
Effect of rifampin on steady-s ...... tonavir in healthy volunteers.
@en
P2093
P2860
P356
P1476
Effect of rifampin on steady-s ...... tonavir in healthy volunteers.
@en
P2093
P2860
P304
P356
10.1128/AAC.00461-06
P407
P577
2006-10-01T00:00:00Z